Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Any company’s management team has a duty to maximize

<< Previous

Bullboard Posts

Next >>

Comment by Yajneon Apr 04, 2021 11:02pm

152 Views

Post# 32935862

RE:RE:RE:RE:RE:RE:RE:Any company’s management team has a duty to maximize

CancerSlayer wrote:
Great post CS. Yes I agree it's virtually impossible to guess sp numbers on if efficacy is established across more that a single indication especially when it is strongly implied that it will also successfully treat many more indications. Having such a novel single/dual treatment approach is in a territory of it's own. One can only hope that the long awaited bidding war would reflect that.

It's hard to put a price on TLT considering its ACT is so novel & versatile. I don't look at our value per indication, because it's so much more than that. Establishing efficacy across more than a single solid tumor type would be impressive & would dramatically change the approach to this company's valuation...as it becomes more evident that we may be sitting on a silver bullet for solid cancers in the name of TLD-1433 (or its improved version). Then consider the inordinate added value x-ray activation (or its equivalent) would bring. Then imagine if all goes well in the infectious disease dept. By this point, it would be a fool's errand trying to assign a value : )

I hope we can remain independent until "at least" we have FDA approval with NMIBC & proven efficacy in at least one other indication. Good luck..